Late-Stage R&D and Bioproduction Unit Team
Late-stage R&D, scale-up and technology transfer for complex biopharmaceuticals production.
Research Focus
iBET’s Bioproduction Unit has extensive expertise in bioprocess development for Advanced Therapy Medicinal Products (ATMPs) such as adeno-associated virus (AAVs) for gene therapy, and recombinant proteins (incl. virus-like particles, VLPs) for vaccines.
The team has been reinforcing iBET’s leadership in these areas, nationally and internationally, while also fostering interaction amongst iBET Units/laboratories and the training of specialized researchers and technicians. Our most recent activities have been centered on the design of robust solutions for product expression, purification and characterization, process scale-up (up to 50 L), and technology transfer to CDMOs.
Areas of Activity
Late-stage R&D
Design of optimized upstream and downstream processes, and implementation of robust bioanalytical tools
Bioprocess scale-up
Establishment of scalable, GMP compliant processes for production of ATMPs (e.g. AAVs for gene therapy and oncolytic virus for cancer treatment) and recombinant proteins (e.g. VLPs for vaccines)
Technology transfer
Transfer of technology to CDMOs, including shadowing of key process operations
António Roldão
Head of the Cell-based Vaccines Development Laboratory & Coordinator of Late-Stage R&D Unit
I am the Coordinator of the Late-Stage R&D Unit at iBET since 2021. In this role, I coordinate and/or manage multiple national and EU funded projects as well as R&D service driven projects focused on vaccines and viral vectors production.
Cristina Peixoto
Head of Downstream Process Development lab, Coordinator of Bioproduction Unit
I coordinate the Bioproduction Unit at iBET since 2021. I have managed more than 50 R&D service driven projects with industrial partners, some of the processes developed are now at the clinical stage.
